A COMPREHENSIVE REVIEW ON SUPERSATURABLE SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM
DOI:
https://doi.org/10.22159/ajpcr.2021.v14i8.41987Keywords:
Solubility, Supersaturable self-nanoemulsifying drug delivery systems, Nanotechnology, Precipitation inhibitors, CancerAbstract
Lipid-based drug delivery systems are extensively reported in the literature for enhancing drug solubility, permeability, and bioavailability. Self-nanoemulsifying drug delivery systems (SNEDDS) are a superior strategy for enhancing solubility and bioavailability of poorly water-soluble compounds and the most prevailing and commercially viable oil-based approach for drugs that exhibit low dissolution rate and inadequate absorption. However, these formulations have few limitations that include in vivo drug precipitation, inferior in vitro in vivo correlation owing to unavailability of in vitro tests, handling issues of liquid formulation, and physicochemical instability of drugs. These limitations are overcome by potential systems such as supersaturable SNEDDS (S-SNEDDS) which are prepared by addition of precipitation inhibitors into formulated SNEDDS to maintain drug supersaturation post dispersion in gastrointestinal tract. These systems improve drug bioavailability and reduce the inconsistency of exposure. In addition, these formulations also help to overcome the drawbacks of liquid and capsule dosage forms. The S-SNEDDS provides an effective approach for improving the dissolution and bioavailability of anti-cancer agents. In this article, an attempt was made to present an overview of SNEDDS, S-SNEDDS, their mechanism, formulation excipients, recent advancements, advantages, and disadvantages of SNEDDS formulations. The article also focuses on reviewing the application of S-SNEDDS in enhancing the solubility and bioavailability of anti-cancer drugs in cancer therapy.
Downloads
References
Haritha B. A review on evaluation of tablets. Formulation Sci Bioavailability 2017;1:1-5.
Hetal PT, Jagruti LD. Influence of excipients on drug absorption via modulation of intestinal transporters activity. Asian J Pharm 2015;9:69-82.
Kunde SD, Bhilegaonkar SH, Godbole AM, Gajre P. Biopharmaceutical classification system: A brief account. Int J Sci Res Methodol 2015;1:20-46.
Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 2013;102:34-42.
Ghadi RR, Dand N. BCS class IV drugs: Highly notorious candidates for formulation development. Drug Deliv Transl Res 2017;248:71-95.
Thakare P, Mogal V, Borase P, Dusane J, Kshirsagar S. A review on self-emulsified drug delivery system. J Pharm Biol Eval 2016;3:140-53.
Mistry R, Sheth NS. Self-emulsifying drug delivery system. Int J Pharm Pharm Sci 2011;3:23-8.
Martin A. Solubility and Distribution Phenomena. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkin; 2011.
Fatouros DG, Karpf DM, Nielsen FS, Mullertz A. Clinical studies with oral lipid-based formulations of poorly soluble compounds. Ther Clin Risk Manag 2007;3:591-604.
Kale AA, Patravale VB. Design and evaluation of self-emulsifying drug delivery systems. (SEDDS) of nimodipine. AAPS PharmSciTech 2008;9:191-6.
Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G. Development of self-microemulsifying drug delivery systems. (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004;274:65-73.
Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Improved oral bioavailability of BCS class 2 compounds by self-nanoemulsifying drug delivery systems. (SNEDDS): The underlying mechanisms for amiodarone and talinolol. Pharm Res 2013;30:3029-44.
Chouksey R, Pandey H, Jain AK, Soni H, Saraogi GK. Preparation and evaluation of the self-emulsifying drug delivery system containing atorvastatin HMGCOA inhibiter. Int J Pharm Pharm Sci 2011;3:147-52.
Shukla JB, Koli A, Ranch K, Rajesh P. Self-micro emulsifying drug delivery system pharma science monitor. J Pharm Pharm Sci 2010;1:13-33.
Shafiq S, Shakeel F, Talegaonkar S. Development and bioavailability assessment of ramiprilnanoemulsion formulation. Eur J Pharm Biopharm 2007;66:227-43.
Shakeel F, Iqbal M, Ezzeldin E. Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. J Pharm Pharmacol 2016;68:772-80.
Chime S, Kenechukwu F, Attama A. Nanoemulsions-advances in formulation, characterization and applications in drug delivery. In: Ali DS, editors. Application of Nanotechnology in Drug Delivery. London: Croatia InTech; 2014. p. 77-111.
Khan AW, Kotta S, Ansari SH. Potentials and challenges in self nanoemulsifying drug delivery systems. Exp Opin Drug Deliv 2012;9:1305-17.
Reddy SM, Reddy MS, Reddy NR, Reddy OM. Formulation and evaluation of novel lipid based solid self-nano emulsifying drug delivery system of repaglinide. Int J Pharm Sci 2014;6:106-10.
Singh B, Garg B, Kaur R, Jain A, Kumar R, Katare OP. Self-nanoemulsifying systems for oral bioavailability enhancement. In: Fabrication and Self-Assembly of Nano Biomaterials. Punjab University: William Andrew; 2016. p. 91-115.
Pallavi M, Nigade Swapnil L, Patil Shradha S, Tiwari. Self-Emulsifying Drug Delivery System (SEDDS). A Review. IJPBS. 2012;2:42-52.
Pouton CW. Lipid formulations for oral administration of drugs non-emulsifying, self-emulsifying and self-micro emulsifying drug delivery systems. Eur J Pharm Sci 2000;11:93-182.
Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems. An approach to enhance oral bioavailability. Drug Discov Today 2010;15:958-65.
Dabros T, Yeung A, Masliyah J, Czarnecki J. Emulsification through area contraction. J Colloid Interface Sci 1999;210:222-4.
Sagar SavaleK. A Review-Self Nanoemulsifying Drug Delivery System (SNEDDS). Int J Chem Pharm Rev Res. 2015;4:385-397.
Bangia JK, Om H. Nanoemulsions, a versatile drug delivery tool. Int J Pharm Sci Res 2015;6:1363-72.
Patel D, Sawant KK. Self-micro-emulsifying drug delivery system: formulation development and biopharmaceutical evaluation of lipophilic drugs. Curr Drug Deliv 2009;6:419-24.
Singh B, Bandopadhyay S, Kapil R, Singh R, Katare O. Self-emulsifying drug delivery systems (SEDDS). Formulation development characterization and applications. Crit Rev Ther Drug Carrier Syst 2009;26:427-521.
Craig DQ, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm 1995;114:103-10.
Nigade PM, Patil S, Tiwari SS. Self-emulsifying drug delivery system (SEDDS): A review. Int J Pharm Biol Sci 2012;2:42-52.
Sharma V, Singh J, Gill B, Harikumar SL. SMEDDS: A novel approach for lipophilic drugs. Int J Pharm Sci Res 2012;3:2441-50.
Savale KS. A review-self nanoemulsifying drug delivery system (SNEDDS). Int J Chem Pharm Rev Res 2015;4:385-97.
Abhishek VG, Salunkhe KS, Chaudhari SR, Gadge PB, Dighe GS, Asati A. A review on, self-micro emulsifying drug delivery system. Am J Pharma Technol Res 2015;5:51-66.
Xi J, Chang Q, Chan CK. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS PharmSci Tech. 2009;10:172-182.
Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231-48.
Harman WN, Porter CJ, Mithani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption the role of lipids and pH. J Pharm Sci 1997;86:269-82.
Shukla Jill B, Akshay RK, Ketan MR, Rajesh KP. Self-micro emulsifying drug delivery system, pharma science monitor. Int J Pharm Sci 2010;1:13-33.
Bhargava P, Bhargava S, Daharwal SJ. Self-emulsifying drug delivery system: An approach to improve the solubility of poorly water-soluble drugs. Adv Res Pharm Biol 2011;1:1-9.
Porter JH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilization using lipid-based delivery systems. Adv Drug Deliv Rev 2008;60:673-91.
Kumar A, Sharma S, Kamble R. Self-emulsifying drug delivery system (SEDDS): Future aspects. Int J Pharm Pharm Sci 2010;2:7-13.
Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci 2009;98:3582-95.
Do Thi T, Van Speybroeck M, Barillaro V. Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. Eur J Pharm Sci 2009;38:479-88.
Kumar S. Role of nano-emulsion in pharmaceutical sciences-a review. Asian J Res Pharm Sci Biotechnol 2014;2:1-15.
Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: Formulation development and bioavailability assessment. Int J Pharm 2001;212:233-46.
Vonderscher J, Meinzer A. Rationale for the development of sandimmune neoral. Transplant Proc 1994;26:2925-7.
Bandyopadhyay S, Katare O, Singh B. Development of optimized supersaturable selfnanoemulsifying systems of ezetimibe: Effect of polymers and efflux transporters. Expert Opin Drug Deliv 2014;11:479-92.
Chen Y, Chen C, Zheng J. Development of a solid supersaturatable selfemulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull 2011;34:278-86.
Gao P, Akrami A, Alvarez F. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci 2009;98:516-28.
Thomas N, Holm R, Garmer M. Supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J 2013;15:219-27.
Kamel AO, Mahmoud AA. Enhancement of human oral bioavailability and in vitro antitumor activity of rosuvastatin via spray dried self nanoemulsifying drug delivery system. J Biomed Nanotechnol 2013;9:26-39.
Seo YG, Kim DH, Ramasamy T. Development of docetaxel-loaded solid selfnanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm 2013;452:412-20.
Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 2003;92:2386-98.
Poelma FG, Breas R, Tukker JJ, Crommelin DJ. Intestinal absorption of drugs: The influence of mixed micelles on on the disappearance kinetics of drugs from the small intestine of the rat. J Pharm Pharmacol 1991;43:317-24.
Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water-soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm 2004;30:221-9.
Dahan A, Hoffman A. Rationalizing the selection of oral lipid-based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water-soluble drugs. J Control Release 2008;129:1-10.
Morozowich W, Gao P, Charton M. Speeding the development of poorly soluble/poorly permeable drugs by SEDDS/S-SEDDS formulations and prodrugs, Part 1. Am Pharm Rev 2006;9:110-4.
Gao P, Charton M, Morozowich W. Speeding the development of poorly soluble/poorly permeable drugs by SEDDS/S-SEDDS formulations and prodrugs, Part 2. Am Pharm Rev 2006;9:16-23.
Pellett MA, Davis AF, Hadgraft J. Effect of supersaturation on membrane transport: 2. Piroxicam. Int J Pharm 1994;111:1-6.
Malgope A, Murthy PN, Ramani R, Dey S. Development of nanoemulsion as carrier for transdermal delivery of Valsartan. Int J Pharm Chem Sci 2013;2:1655-65.
Sokolov YV. Nanoemulsions as prospective drug delivery systems. News Pharm 2014;1:21-5.
Shafiq S, Shakeel F, Talegaonkar S, Azeem A, Ahmad FJ, Khar RK. The nano-emulsion system a review. Eur J Pharm Biopharm 2007;66:227-43.
Masoud AM, Baie SH, Arafat OM. The influence of sucrose ester surfactants and different storage condition on the preparation of nano-emulsion. Int J Drug Formulation Res 2012;3:72-87.
Mazumder J, Pathak D, Kumria R. Evaluation of antacid activity of microemulsion formulation of blend of essential oil. Int J Pharm Sci Drug Res 2015;7:163-7.
Mirza MA, Khan MJ, Iqbal Z. Nanoemulsion technology in unani medicine. Int J Adv Pharm Med Bioallied Sci 2015;3:70-4.
Kumar M, Pathak K. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm 2009;35:387-95.
Kanwale NP, Gavali D, Patil D, Bhaskar R, Dhas A, Dwivedi A. Nanoemulsion, a new system for drug delivery. World J Pharm Sci 2015;4:310-26.
Bhosale RR, Osmani RA, Ghodake PP, Shaikh SM, Chavan SR. Nanoemulsion, a review on novel profusion in advanced drug delivery. Indian J Pharm Biol Res 2014;2:122-7.
Reddy BA, Debnath MS, Babu MN. Nanoemulsion, a novel approach for lipophilic drugs a review. Asian J Pharm Res 2013;3:84-92.
Lu JL, Wang JC, Zhao SX, Liu XY, Zhao H, Zhang X, et al. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. Eur J Pharm Biopharm 2008;69:899-907.
Veltkamp SA, Thijssen B, Garrigue JS, Lambert G, Lallemand F, Binlich F, et al. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. Br J Cancer 2006;95:729-34.
Hanahan D, Weinberg RA. Hallmarks of Cancer: The next generation. Cell 2011;144:646-74.
Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev 2017;108:25-38.
Zhang X, Yi Y, Qi J. Controlled release of cyclosporine A selfnanoemulsifying systems from osmotic pump tablets: Near zero-order release and pharmacokinetics in dogs. Int J Pharm 2013;452:233-40.
Miao Y, Chen G, Ren L. Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect. Drug Deliv 2014;23:1- 10.
Park MJ, Balakrishnan P, Yang SG. Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine. Int J Pharm 2013;441:757-64.
Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release 2011;153:106-16.
Dünnhaupt S, Kammona O, Waldner C. Nano-carrier systems: Strategies to overcome the mucus gel barrier. Eur J Pharm Biopharm 2015;96:447-53.
Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1-26.
Sakloetsakun D, Dünnhaupt S, Barthelmes J, Perera G, Schnürch AB. Combining two technologies: Multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. Int J Biol Macromol 2013;61:363-72.
Karamanidou T, Karidi K, Bourganis V, Kontonikola K, Kammona O, Kiparissides C. Effective incorporation of insulin in mucus permeating self-nanoemulsifying drug delivery systems. Eur J Pharm Biopharm 2015;97:223-9.
Qi X, Wang L, Zhu J. Self-double-emulsifying drug delivery system (SDEDDS): A new way for oral delivery of drugs with high solubility and low permeability. Int J Pharm 2011;409:245-51.
Feeney OM, Williams HD, Pouton CW. ‘Stealth’lipid-based formulations: Poly (ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water-soluble drug. J Controlled Release 2014;192:219-27.
Barthelmes J, Dünnhaupt S, Hombach J. Thiomer nanoparticles: Stabilization via covalent cross-linking. Drug Deliv 2011;18:613-9.
Zhao T, Maniglio D, Chen J, Chen B, Motta A, Migliaresi C. Design and optimization of self-nanoemulsifying formulations for lipophilic drugs. Nanotechnology 2015;26:12510.
Krishnaiah YS. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Available 2010;2:28-36.
Kourentas A, Vertzoni M, Symillides M, Hen B, Brouwers J, Augustijns P, et al. In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. Int J Pharm 2016;515:352-8.
Frampton JE. Entrectinib: A review in NTRK+ solid tumours and ROS1+ NSCLC. Drugs 2021;81:697-708.
Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, et al. The European medicines agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements. ESMO Open 2021;6:100087.
Drilon A, Siena S, Ou SH, Patel M, Ahn MJ, Lee J, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA- 372-001 and STARTRK-1) Cancer Discov 2017;7:400-9.
Araujo JM, Gomez AC, Pinto JA, Rolfo C, Raez LE. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. Hematol Oncol Stem Cell Ther 2020;2020:30177.
Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, et al. Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 2016;15:628-39.
Liu D, Offin M, Harnicar S, Li BT, Drilon A. Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag 2018;14:1247-52.
Amboldi N, Pulci R, Texido G, Bosotti R, Magnaghi P, Felder E, et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 2016;15:628-39.
Drilon A, Sankhala KK, Liu SV, Cho BC, Blakely C, Chee CE, et al. Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions. Cancer Res 2017;77:CT060.
Siena S, Doebele RC, Shaw AT, Karapetis CS, Tan DS, Cho BC, et al. Efficacy of entrectinib in patients (PTS) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. J Clin Oncol 2019;37:3017.
Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol 2021;17:389-402.
Hoy SM. Pemigatinib: First approval. Drugs 2020;80:923-9.
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al- Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol 2020;21:671-84.
Romero D. Benefit from pemigatinib in cholangiocarcinoma. Nat Rev Clin Oncol 2020;17:337.
Published
How to Cite
Issue
Section
Copyright (c) 2021 Bhikshapathi D.V.R.N.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
